Electroacupuncture to treat gastroesophageal reflux disease: study protocol for a randomized controlled trial

Gajin Han, Jungtae Leem, Hojung Lee, Junhee Lee, Gajin Han, Jungtae Leem, Hojung Lee, Junhee Lee

Abstract

Background: Gastroesophageal reflux disease lowers the quality of life and increases medical costs. Electroacupuncture has been used to ease symptoms and improve gastrointestinal motility in patients with gastroesophageal reflux disease. The main purposes of this study are to evaluate the efficacy and safety of this procedure.

Methods/design: This is a protocol for a randomized, patient-blinded, assessor-blinded, sham-controlled trial. Sixty participants with symptoms of gastroesophageal reflux disease, who have previously undergone standard treatment, will be recruited from August 2015 at Kyung Hee University Korean Medicine Hospital. The participants will be allocated to either the electroacupuncture (n = 30) or the sham electroacupuncture group (n = 30); the allocation will be concealed from both the participants and the assessors. The EA group will undergo penetrating acupuncture at 18 fixed points and two optional points chosen using the pattern identification for gastroesophageal reflux disease. Electrical stimulation will be applied at some of the acupoints. The sham electroacupuncture group will undergo nonpenetrating acupuncture without electrical stimulation at 18 nonspecific points, each of which will be only 2 cm away from the true acupoints used in the electroacupuncture group. In both groups, the procedure will be performed using the Park device. The treatment will last for 6 weeks (with two sessions each week), and the outcome will be evaluated at baseline, 3 weeks, and 6 weeks. The primary outcome will be the proportion of responders with adequate symptom relief, whereas the secondary outcomes will comprise the results of the Nepean dyspepsia index; the Korean gastrointestinal symptom rating scale; the EQ-5D™; levels of gastrin, motilin, and inflammatory cytokines; the perceived stress scale; the qi-stagnation questionnaire; the patient global impression of change; and the spleen qi deficiency questionnaire.

Discussion: The results of this trial will provide information about the efficacy and safety of electroacupuncture in the treatment of gastroesophageal reflux disease symptoms, as well as evidence regarding the use of electroacupuncture to treat gastroesophageal reflux disease in real clinical practice.

Trial registration: Clinical Research Information Service Identifier, KCT0001653 . Registered on 12 October 2015.

Keywords: Electroacupuncture; Gastroesophageal reflux disease; Park device; Pattern identification; Proportion of responders.

Figures

Fig. 1
Fig. 1
Timeline of the study

References

    1. Goh K-L. Gastroesophageal reflux disease in Asia: A historical perspective and present challenges. J Gastroenterol Hepatol. 2011;26(Suppl 1):2–10. doi: 10.1111/j.1440-1746.2010.06534.x.
    1. Ho KY, Cheung TK, Wong BC. Gastroesophageal reflux disease in Asian countries: disorder of nature or nurture? J Gastroenterol Hepatol. 2006;21:1362–5. doi: 10.1111/j.1440-1746.2006.04254.x.
    1. Ho KY. Gastroesophageal reflux disease in Asia: a condition in evolution. J Gastroenterol Hepatol. 2008;23:716–22. doi: 10.1111/j.1440-1746.2008.05380.x.
    1. Hayden CW, Bernstein CN, Hall RA, Vakil N, Garewal HS, Fass R. Usage of supplemental alternative medicine by community-based patients with gastroesophageal reflux disease (GERD) Dig Dis Sci. 2002;47:1–8. doi: 10.1023/A:1013264730992.
    1. Dickman R, Schiff E, Holland A, Wright C, Sarela SR, Han B, et al. Clinical trial: acupuncture vs. doubling the proton pump inhibitor dose in refractory heartburn. Aliment Pharmacol Ther. 2007;26:1333–44. doi: 10.1111/j.1365-2036.2007.03520.x.
    1. El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther. 2010;32:720–37. doi: 10.1111/j.1365-2036.2010.04406.x.
    1. Zhang C, Guo L, Guo X, Guo X, Li G. Clinical curative effect of electroacupuncture combined with zhizhukuanzhong capsules for treating gastroesophageal reflux disease. J Tradit Chin Med. 2012;32:364–71. doi: 10.1016/S0254-6272(13)60039-4.
    1. Qian LW, Lin YP. Effect of electroacupuncture at zusanli (ST36) point in regulating the pylorus peristaltic function. Zhongguo Zhong Xi Yi Jie He Za Zhi. 1993;13:336–9.
    1. Shuai X, Xie P, Liu J, Xiang Y, Li J, Lan Y. Different effects of electroacupuncture on esophageal motility and serum hormones in cats with esophagitis. Dis Esophagus Off J Int Soc Dis Esophagus ISDE. 2008;21:170–5. doi: 10.1111/j.1442-2050.2007.00757.x.
    1. Zhou L. The regulatory function of acupuncture of the stomach. Acupunct Res. 1986;11:274–9.
    1. Wang C, Zhou D-F, Shuai X-W, Liu J-X, Xie P-Y. Effects and mechanisms of electroacupuncture at PC6 on frequency of transient lower esophageal sphincter relaxation in cats. World J Gastroenterol. 2007;13:4873–80. doi: 10.3748/wjg.v13.i36.4873.
    1. Xing J, Chen JDZ. Alterations of gastrointestinal motility in obesity. Obes Res. 2004;12:1723–32. doi: 10.1038/oby.2004.213.
    1. Chang C-S, Chou J-W, Wu C, Chang Y-H, Ko C-W, Chen G-H. Atropine-induced gastric dysrhythmia is not normalized by electroacupuncture. Dig Dis Sci. 2002;47:2466–72. doi: 10.1023/A:1020599707395.
    1. Tougas G, Yuan LY, Radamaker JW, Chiverton SG, Hunt RH. Effect of acupuncture on gastric acid secretion in healthy male volunteers. Dig Dis Sci. 1992;37:1576–82. doi: 10.1007/BF01296505.
    1. Niu W-X, He G-D, Liu H, Qin X-Y. Effects and probable mechanisms of electroacupuncture at the Zusanli point on upper gastrointestinal motility in rabbits. J Gastroenterol Hepatol. 2007;22:1683–9. doi: 10.1111/j.1440-1746.2007.05049.x.
    1. Lee CH, Kim D-K, Yook T-H, Sasaki M, Kitamura N. Effectiveness of electroacupuncture at Zusanli (ST36) on the immunohistochemical density of enteroendocrine cells related to gastrointestinal function. J Acupunct Meridian Stud. 2012;5:63–71. doi: 10.1016/j.jams.2012.01.002.
    1. Rieder F, Biancani P, Harnett K, Yerian L, Falk GW. Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis. Am J Physiol Gastrointest Liver Physiol. 2010;298:G571–81. doi: 10.1152/ajpgi.00454.2009.
    1. Jeong YJ, Lee DH, Choi TH, Hwang TJ, Lee BH, Nah JC, et al. Clinical analysis of recurrence rate and symptom improvement in gastro-esophageal reflux disease patients. Korean J Gastroenterol. 2010;55:100–8. doi: 10.4166/kjg.2010.55.2.100.
    1. Chiu C-T, Hsu C-M, Wang C-C, Chang J-J, Sung C-M, Lin C-J, et al. Randomised clinical trial: sodium alginate oral suspension is non-inferior to omeprazole in the treatment of patients with non-erosive gastroesophageal disease. Aliment Pharmacol Ther. 2013;38:1054–64. doi: 10.1111/apt.12482.
    1. MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, et al. STRICTA revision group: Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;7 doi: 10.1371/journal.pmed.1000261.
    1. Han G, Leem J, Lee N, Kim J, Park J, Lee J. Development of a standard tool for pattern identification of gastroesophageal reflux disease (GERD) J Korean Orient Intern Med. 2015;36:122–52. doi: 10.13048/jkm.15039.
    1. Park J, White A, Lee H, Ernst E. Development of a new sham needle. Acupunct Med. 1999;17:110–2. doi: 10.1136/aim.17.2.110.
    1. Smith P, Mosscrop D, Davies S, Sloan P, Al-Ani Z. The efficacy of acupuncture in the treatment of temporomandibular joint myofascial pain: a randomised controlled trial. J Dent. 2007;35:259–67. doi: 10.1016/j.jdent.2006.09.004.
    1. Whale CA, MacLaran SJA, Whale CI, Barnett M. Pilot study to assess the credibility of acupuncture in acute exacerbations of chronic obstructive pulmonary disease. Acupunct Med. 2009;27:13–5. doi: 10.1136/aim.2008.000232.
    1. Chae Y, Lee H, Kim H, Sohn H, Park J-H, Park H-J. The neural substrates of verum acupuncture compared to non-penetrating placebo needle: an fMRI study. Neurosci Lett. 2009;450:80–4. doi: 10.1016/j.neulet.2008.11.048.
    1. Jung H, Hong S, Jo Y, Jeon S, Cho Y, Lee K, Lee J, Park H, Shin E, Lee S, Han S. The Korean Society of Neurogastroenterology and Motility: updated guidelines for gastroesophageal reflux disease. Korean J Gastroenterol. 2012;2012(60):195–218. doi: 10.4166/kjg.2012.60.4.195.
    1. Kahrilas PJ, Shaheen NJ, Vaezi MF, American Gastroenterological Association Institute, Clinical Practice and Quality Management Committee American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135:1392–413. doi: 10.1053/j.gastro.2008.08.044.
    1. Design of Treatment Trials Committee. Irvine EJ, Whitehead WE, Chey WD, Matsueda K, Shaw M, et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology. 2006;130:1538. doi: 10.1053/j.gastro.2005.11.058.
    1. Talley NJ, Van Zanten SV, Saez LR, Dukes G, Perschy T, Heath M, et al. A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia. Aliment Pharmacol Ther. 2001;15:525–37. doi: 10.1046/j.1365-2036.2001.00941.x.
    1. Han G, Ko S-J, Park J-W, Kim J, Yeo I, Lee H, et al. Acupuncture for functional dyspepsia: study protocol for a two-center, randomized controlled trial. Trials. 2014;15:89. doi: 10.1186/1745-6215-15-89.
    1. Bolier EA, Kessing BF, Smout AJ, Bredenoord AJ. Systematic review: questionnaires for assessment of gastroesophageal reflux disease. Dis Esophagus. 2015;28:105–20. doi: 10.1111/dote.12163.
    1. Talley NJ, Haque M, Wyeth JW, Stace NH, Tytgat GN, Stanghellini V, et al. Development of a new dyspepsia impact scale: the Nepean Dyspepsia Index. Aliment Pharmacol Ther. 1999;13:225–35. doi: 10.1046/j.1365-2036.1999.00445.x.
    1. Talley NJ, Verlinden M, Jones M. Quality of life in functional dyspepsia: responsiveness of the Nepean Dyspepsia Index and development of a new 10-item short form. Aliment Pharmacol Ther. 2001;15:207–16. doi: 10.1046/j.1365-2036.2001.00900.x.
    1. Lee S, Choi S, Cho Y, Choi M. Validation of the Nepean dyspepsia index - Korean version. Kor J Neurogastroenterol Mot. 2003;9(suppl):48S.
    1. Stein HJ, Barlow AP, DeMeester TR, Hinder RA. Complications of gastroesophageal reflux disease. Role of the lower esophageal sphincter, esophageal acid and acid/alkaline exposure, and duodenogastric reflux. Ann Surg. 1992;216:35–43. doi: 10.1097/00000658-199207000-00006.
    1. Lux G, Rösch W, Domschke S, Domschke W, Wünsch E, Jaeger E, et al. Intravenous 13-Nle-motilin increases the human lower esophageal sphincter pressure. Scand J Gastroenterol Suppl. 1976;39:75–9.
    1. Castell DO, Harris LD. Hormonal control of gastroesophageal-sphincter strength. N Engl J Med. 1970;282:886–9. doi: 10.1056/NEJM197004162821602.
    1. Lepsien G, Dietrich K. Peptone stimulation of the lower esophageal sphincter in patients with reflux disease. Z Für Gastroenterol. 1988;26:209–16.
    1. Korimilli A, Parkman HP. Effect of atilmotin, a motilin receptor agonist, on esophageal, lower esophageal sphincter, and gastric pressures. Dig Dis Sci. 2010;55:300–6. doi: 10.1007/s10620-009-1056-1.
    1. Straathof JW, Lamers CB, Masclee AA. Effect of gastrin-17 on lower esophageal sphincter characteristics in man. Dig Dis Sci. 1997;42:2547–51. doi: 10.1023/A:1018872814428.
    1. Fitzgerald RC, Onwuegbusi BA, Bajaj-Elliott M, Saeed IT, Burnham WR, Farthing MJG. Diversity in the oesophageal phenotypic response to gastrooesophageal reflux: immunological determinants. Gut. 2002;50:451–9. doi: 10.1136/gut.50.4.451.
    1. Isomoto H, Saenko VA, Kanazawa Y, Nishi Y, Ohtsuru A, Inoue K, et al. Enhanced expression of interleukin-8 and activation of nuclear factor kappa-B in endoscopy-negative gastroesophageal reflux disease. Am J Gastroenterol. 2004;99:589–97. doi: 10.1111/j.1572-0241.2004.04110.x.
    1. Yoshida N, Uchiyama K, Kuroda M, Sakuma K, Kokura S, Ichikawa H, et al. Interleukin-8 expression in the esophageal mucosa of patients with gastroesophageal reflux disease. Scand J Gastroenterol. 2004;39:816–22. doi: 10.1080/00365520410006729.
    1. Mahadeva S, Wee H-L, Goh K-L, Thumboo J. The EQ-5D (Euroqol) is a valid generic instrument for measuring quality of life in patients with dyspepsia. BMC Gastroenterol. 2009;9:20. doi: 10.1186/1471-230X-9-20.
    1. Kind P. Quality of life and pharmacoeconomics in clinical trials. Philadelphia: Lippincott-Raven; 1996. The EuroQoL instrument: an index of health-related quality of life; pp. 191–201.
    1. Kang E, Park H, Kim N, Jo MW, Shin H. A valuation of health status using EQ-5D. Korean J Health Econ Policy. 2006;12:19–43.
    1. Kwon S, Jung H, Hong J, Park H. Diagnostic validity of the Korean Gastrointestinal Symptom Rating Scale (KGSRS) in the assessment of gastroesophageal reflux disease. Ewha Med J. 2008;31:73–80. doi: 10.12771/emj.2008.31.2.73.
    1. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983;24:385–96. doi: 10.2307/2136404.
    1. Lee E-H, Chung BY, Suh C-H, Jung J-Y. Korean versions of the Perceived Stress Scale (PSS-14, 10 and 4): psychometric evaluation in patients with chronic disease. Scand J Caring Sci. 2015;29:183–92. doi: 10.1111/scs.12131.
    1. Bang H, Ni L, Davis CE. Assessment of blinding in clinical trials. Control Clin Trials. 2004;25:143–56. doi: 10.1016/j.cct.2003.10.016.
    1. Dennehy EB, Webb A, Suppes T. Assessment of beliefs in the effectiveness of acupuncture for treatment of psychiatric symptoms. J Altern Complement Med N Y N. 2002;8:421–5. doi: 10.1089/107555302760253612.
    1. Farrar JT, Young JP, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94:149–58. doi: 10.1016/S0304-3959(01)00349-9.
    1. Han G, Seon J, Son J, Oh S, Park Y, Jeong Y, et al. Correlation between xerostomia, stress, and Qi movement stagnation in halitosis patients. J Korean Orient Intern Med. 2010;31:488–99.
    1. Oh HW. Study on the development of a standard instrument of diagnosis and assessment for spleen Qi deficiency pattern. J Korean Med Sci. 2014;35:157–70. doi: 10.13048/jkm.14015.
    1. Yu D. Lansoprazole and mosapride with acupuncture treatment for 56 patients with non-erosive gastroesophageal reflux disease. Chinese Community Doctors. 2011;15:177–8.
    1. Zhu D, Gao Y, Chang J, Kong J. Placebo acupuncture devices: considerations for acupuncture research. Evid-Based Complement Altern Med ECAM. 2013;2013:628907.
    1. Pastore LM, Williams CD, Jenkins J, Patrie JT. True and sham acupuncture produced similar frequency of ovulation and improved LH to FSH ratios in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2011;96:3143–50. doi: 10.1210/jc.2011-1126.
    1. Park J, White A, Stevinson C, Ernst E, James M. Validating a new non-penetrating sham acupuncture device: two randomised controlled trials. Acupunct Med J Br Med Acupunct Soc. 2002;20:168–74. doi: 10.1136/aim.20.4.168.
    1. Moore RA, Moore OA, Derry S, McQuay HJ. Numbers needed to treat calculated from responder rates give a better indication of efficacy in osteoarthritis trials than mean pain scores. Arthritis Res Ther. 2008;10:R39. doi: 10.1186/ar2394.
    1. Schulz KF, Chalmers I, Altman DG. The landscape and lexicon of blinding in randomized trials. Ann Intern Med. 2002;136:254–9. doi: 10.7326/0003-4819-136-3-200202050-00022.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться